A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL

Figures & data

Table 1. Baseline characteristics of patients.

Case	Age (years)	Sex	Onset	WBC count at the first diagnosis (×10^9/L)	BM tumor load at the first diagnosis	Gene mutation	Time to CR	MRD after CR	Risk stratification
1	31	Male	Swollen cervical lymph nodes	9.34	40%	–	<4 weeks	(+)	High risk
2	18	Male	Nosebleed	15.53	92%	RUNX1 and NOTCH1 mutation	>4 weeks	(+)	High risk
3	44	Male	Mediastinal mass	8.99	52%	Clonal rearrangements of TCRG gene	<4 weeks	(-)	High risk
4	54	Male	Mediastinal mass	41.97	98%	–	>4 weeks	(+)	High risk
5	28	Male	Mediastinal mass	18.8	45%	Accompanied with myeloid expression, NOTCH1 and CEBPA mutation	>4 weeks	(-)	High risk
6	28	Male	Swollen cervical lymph nodes	3.27	68%	Accompanied with CD19 and CD79a expression	>4 weeks	(+)	High risk

Note: MRD: minimal residual disease; BM: Bone marrow; CR: complete remission.

Table 2. Pre-transplant and transplant-related medical conditions of the patients.

Case	Induction regimen	Pre-transplant disease status/MRD	Transplantation conditioning regimen	HLA Matching
1	Hyper-CVAD	CR1 + CNSL/(+)	TMLI + Dac/Ara-C/Cy/ATG	Haplo-HSCT
2	Hyper-CVAD	CR1/(-)	TBI + Ara-C/BCNU/Cy/ATG	Haplo-HSCT
3	P-CIOD	CR1/(-)	Partial irradiation + Dac/Ara-C/Bu/Mel/Flu/ATG	Haplo-HSCT
4	P-CIOD、D-CAG	CR2/(+)	TMLI + Dac/Ara-C/Cy/ATG	Haplo-HSCT
5	VDCLP	CR1/(-)	Partial irradiation + Dac/Ara-C/Bu/Cy/ATG	Haplo-HSCT
6	Hyper-CVAD、CAG	CR1/(+)	Partial irradiation + Dac/Ara-C/Bu/Cy/ATG	Haplo-HSCT

Note: Hyper-CVAD: cyclophosphamide, vindesine, doxorubicin, dexamethasone; P-CIOD (modified-VDCLP): Pegaspargase, cyclophosphamide, Idarubicin, vindesine, dexamethasone; D-CAG: dexamethasone, cytarabine, cytarabine, cytarabine. VDCLP: vindesine, daunorubicin, cyclophosphamide, asparaginase, prednisone; MRD: minimal residual disease; CR1: First complete remission;CR2: Secondary complete remission;CNSL: central nervous system leukemia; TBI: total body irradiation; TMLI: total marrow and lymphoid irradiation; Dac: decitabine; Ara-C: cytarabine; Cy: cyclophosphamide; Mel: melphalan; BCNU: carmustine; ATG: rabbit-derived antithymocyte globulin; Haplo-HSCT：Haploidentical-hematopoietic stem cell transplantation

Figure 1. Progression-free survival (PFS) of the six patients.

Figure 2. Days of treatment efficacy and survival with the six patients.

Table 3. Patients with post-transplant conditions.

Case	Post-transplant disease status/MRD	Chidamide	Post-transplant recurrence	aGVHD	cGVHD	PFS(d)	OS(d)	Outcome
1	CR + CNSL/(-)	5 mg biw	No	–	–	1335	1335	Survival
2	CR/(-)	5 mg biw	No	–	-	1166	1166	Survival
3	CR/(-)	5 mg biw	No	–	–	920	920	Survival
4	CR/(-)	5 mg biw	No	–	–	737	737	Survival
5	CR/((-)	5 mg biw	Yes	Grade I (skin)	–	203	570	Loss of follow-up
6	CR/(-)	5 mg biw	Yes	Grade II (skin and GI tract)	–	170	565	Survival

Note: MRD: minimal residual disease; CR: complete remission; CNSL: central nervous system leukemia; biw: twice a week; aGVHD: acute graft versus host disease; cGVHD: chronic graft versus host disease; PFS: progression-free survival; OS: overall survival.

Table 4. Adverse effects of Chidamide maintenance therapy.

Adverse effect	Grade 1	Grade 2	Grade 3	Grade 4
Neutropenia	2	0	2	1
Thrombocytopenia	0	2	3	0
Anemia	0	0	1	0
Abnormal liver function	0	2	0	0
Fatigue	1	0	0	0
Vomiting	2	0	0	0

Note: There are six cases in total.

Data availability statement

All data generated or analyzed during this study are included in this article.